Five Prime Therapeutics’ FGFR2b-targeted drug combined with chemotherapy improved survival in a phase 2 trial.
Gritstone Oncology has expanded a phase 2 clinical trial of its personalized cell therapy to include patients with gastric cancer.
Bristol Myers Squibb’s Opdivo improved survival in previously untreated gastric cancer patients in a trial presented at ESMO20.
MacroGenics received orphan drug designation from the FDA for its investigational gastric cancer drug margetuximab.
An early trial of AstraZeneca’s MET inhibitor savolitinib in gastric cancer revealed mutations that confer drug resistance.